Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

BiTEs: More Than a Nibble for Lymphoma and Myeloma

July 13th 2021

Despite the failure of several strategies to improve the outcomes of patients with newly diagnosed diffuse large B-cell lymphoma, there appears to be substantial and growing progress in the treatment of relapsed disease.

Standard Induction for Newly Diagnosed Symptomatic Myeloma

July 13th 2021

Experts in multiple myeloma comment on standard induction therapy for patients with newly diagnosed symptomatic myeloma and consider recommended triplet regimens.

Low Antibody-Mediated Responses to mRNA COVID-19 Vaccine Observed in CLL, Elderly Myeloma

July 13th 2021

The BNT162b2 mRNA COVID-19 vaccine may demonstrate decreased efficacy in patients with certain types of hematologic cancers, such as chronic lymphocytic leukemia and multiple myeloma.

Overview of Newly Diagnosed Multiple Myeloma

July 13th 2021

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss the diagnostic work-up for a patient with newly diagnosed multiple myeloma and the impact of age and frailty scores on transplant eligibility.

FDA Approves Subcutaneous Daratumumab Plus Pd for Multiple Myeloma at First or Subsequent Relapse

July 12th 2021

The FDA has approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro) plus pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy, including lenalidomide and a proteasome inhibitor

Usmani Underscores New and Updated Data Across Myeloma Paradigm

July 9th 2021

Although the armamentarium of multiple myeloma is rich with available treatment options, novel triplet regimens, maintenance therapies, and targets beyond BCMA are further expanding the paradigm across the newly diagnosed, early-relapse, and late-relapse disease states.

Melphalan Flufenamide Shows Mixed Findings in Relapsed/Refractory Myeloma, Leads to Partial Clinical Hold

July 8th 2021

The combination of INN melphalan flufenamide and dexamethasone was found to induce a superior progression-free survival benefit over pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma who had previously received 2 to 4 lines of therapy, meeting the primary end point of the phase 3 OCEAN trial.

Dr. Sperling on Future Research Directions With Ide-Cel in Multiple Myeloma

July 8th 2021

Adam Sperling, MD, PhD, discusses future research directions with idecabtagene vicleucel for the treatment of patients with multiple myeloma.

Dr. Davies on Isatuximab-Based Combinations in Relapsed/Refractory Multiple Myeloma

July 6th 2021

Faith Davies, MD, discusses the approval of isatuximab-irfc-based combinations for patients with relapsed/refractory multiple myeloma.

Dr. Davies on the Next Steps for CAR T-Cell Therapy in Relapsed/Refractory Myeloma

July 1st 2021

Faith E. Davies, MD, discusses the next steps for CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Nadeem on the Integration of Isatuximab in Relapsed/Refractory Multiple Myeloma

June 29th 2021

Omar Nadeem, MD, discusses the integration of isatuximab-irfc in relapsed/refractory multiple myeloma.

Isatuximab Combination Looks to Improve Outcomes for Early Relapsed Multiple Myeloma

June 28th 2021

Thomas G. Martin, MD, speaks to the FDA approval of isatuximab, carfilzomib, and dexamethasone, and potential future directors for isatuximab.

What’s Coming Next in Relapsed/Refractory Multiple Myeloma

June 25th 2021

Key opinion leaders remark about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.

Considering Patient-, Treatment-, and Disease-Related Factors in Myeloma

June 25th 2021

Factors to consider when choosing the optimal treatment approach after the first relapse of multiple myeloma.

Subcutaneous Daratumumab Approved in Europe for Newly Diagnosed Light-Chain Amyloidosis, Pretreated Myeloma

June 22nd 2021

The European Commission has granted marketing authorization for the expanded use of subcutaneous daratumumab for use in 2 new indications.

Dr. Bianchi on Diagnostic Factors for AL Amyloidosis

June 22nd 2021

Giada Bianchi, MD, discusses diagnostic factors for light chain amyloidosis.

Dr. Nadeem on the Emergence of Quadruplet Regimens in Multiple Myeloma

June 21st 2021

Omar Nadeem, MD, discusses the emergence of quadruplet regimens in multiple myeloma.

Navigating Newfound Options, MRD Assessment, and Emerging Approaches in Multiple Myeloma

June 21st 2021

The expanding therapeutic landscape in multiple myeloma is poised to integrate daratumumab-based quadruplet therapies and novel cellular therapies as standard options for patients with newly diagnosed and relapsed/refractory disease.

Impressive CAR T-Cell Data Point to New Future in Relapsed/Refractory Myeloma

June 21st 2021

C. Ola Landgren, MD, PhD, focuses on the cellular- and immunotherapy-based elements from the event and where these modern therapies optimally fit in multiple myeloma.

Selecting Appropriate Therapy for Patients With Relapsed/Refractory Multiple Myeloma

June 18th 2021

James Hoffman, MD, and Joshua Richter, MD, discuss the IKEMA study, the appropriate selection of therapy, and the differences between various options.